

**CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PARASYMPATHETIC ACTIVITY**Narinder Kaur<sup>1</sup>, Sukhjinder Kaur Dhillon<sup>2</sup><sup>1</sup>Associate Professor, Department of Physiology, Affiliated to Punjab Medical Council, Punjab.<sup>2</sup>Professor, Department of Physiology, Affiliated to Punjab Medical Council, Punjab.**ABSTRACT****BACKGROUND**

Chronic Obstructive pulmonary disease is the name of a group of chronic and slowly progressive respiratory disorders characterized by decreased expiratory flow during forced exhalation. COPD broadly consists of two pathological conditions- emphysema and chronic bronchitis. Autonomic abnormalities have been consistently found in COPD. The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases. So, this study was done to study changes in parasympathetic activity in patients of COPD and to compare them with normal subjects.

**MATERIALS AND METHODS**

The study was carried out on 60 male COPD patients and 40 healthy subjects taken as controls. For testing parasympathetic activity, heart rate variation with postural change, Valsalva manoeuvre and deep breathing were recorded.

**RESULTS**

The mean values of 30:15 ratio showed significant decline in COPD patients as compared to normal subjects. The variation in heart rate in response to Valsalva manoeuvre and in response to deep breathing was highly significant between the two groups.

**CONCLUSION**

From the results thus obtained, it can be concluded that there is significant decrease of parasympathetic nervous system activity in patients of COPD as compared to controls.

**KEYWORDS**

Chronic Obstructive Pulmonary Disease, Parasympathetic Activity, Valsalva Manoeuvre, Deep Breathing Test, Heart Rate Variation

**HOW TO CITE THIS ARTICLE:** Kaur N, Dhillon SK. Chronic obstructive pulmonary disease and parasympathetic activity. J. Evid. Based Med. Healthc. 2019; 6(10), 800-802. DOI: 10.18410/jebmh/2019/165

**BACKGROUND**

Chronic obstructive pulmonary disease is a chronic disease characterized by irreversible decline of FEV<sub>1</sub> (forced expiratory volume in first second), dyspnoea and progressive deterioration of health status. After diagnosis 10-year survival rate is 50% with more than one third of patients dying due to respiratory insufficiency.<sup>1</sup> Forced expiratory volume in 1<sup>st</sup> second is the spirometric index most commonly used to detect the presence of COPD, to mark its severity and to determine bronchodilator response.<sup>2</sup> Air pollution, tobacco smoking and occupational hazards are major risk factors for COPD.<sup>3</sup> The systemic effects of COPD include oxidative stress and altered circulating levels of inflammatory mediators and acute phase proteins.<sup>4</sup> Cardiovascular disease is one of the important causes of death and hospitalization among patients with COPD.<sup>5</sup>

Neurohumoral activation has been shown to be present in hypoxic patients with COPD which may have negative consequences namely inflammation, cachexia, skeletal muscle dysfunction and cardiovascular disease.<sup>6</sup> Abnormalities in both parasympathetic and sympathetic nervous system in COPD patients have been demonstrated in many studies.<sup>7</sup> so the present study was conducted to record changes in parasympathetic activity in male patients with COPD and findings compared to observations recorded in normal subjects.

**MATERIALS AND METHODS**

The study was carried out on 60 male Chronic Obstructive Pulmonary disease patients and 40 healthy controls and these were designated as group-I and group-II, respectively. Study group subjects were taken from TB and Chest department of the institute and healthy controls were taken from the general population. Written informed consent was taken from all the subjects. Permission for the study was taken from the institutional ethical committee. Detailed history and physical examination of all the subjects and patients was carried out. For testing parasympathetic system following tests were done:

*Financial or Other, Competing Interest: None.*

*Submission 22-02-2019, Peer Review 25-02-2019,*

*Acceptance 06-03-2019, Published 11-03-2019.*

*Corresponding Author:*

*Dr. Narinder Kaur,*

*Associate Professor,*

*Department of Physiology,*

*Government Medical College,*

*Amritsar, Punjab.*

*E-mail: mana.doc1565@gmail.com*

*DOI: 10.18410/jebmh/2019/165*



### 1. Heart Rate Response to Postural Change (30:15 ratio).

The subject was made to lie quietly on the couch and the heart rate was continuously monitored on the electrocardiograph. The subject was then asked to stand unaided and the point at starting to stand was marked on electrocardiograph. The shortest R-R interval at or around 15<sup>th</sup> beat and the longest R-R interval at around the 30<sup>th</sup> beat after standing was measured. Ratio of 1 or less than one is considered abnormal.

30:15 ratio= Longest R-R interval at beat 30 after standing/shortest R-R interval at beat 15 after standing.

### 2. Heart Rate Response to Valsalva Manoeuvre (Valsalva Ratio)

The subject was asked to exhale into the mouth piece connected to mercury manometer and holding it at a pressure of 40 mmHg for 15 secs. during this manoeuvre and 45 seconds subsequent to this, ECG was recorded, and Valsalva ratio calculated, which is the ratio between maximal R-R interval and minimal R-R interval. Ratio of less than one or equal to 1.10 is considered as abnormal.

### 3. Heart Rate Variation with Deep Respiration

Deep breathing at six breaths a minute is the most convenient and reproducible technique. In this test the subject was asked to breathe deeply at six breaths per minute i.e. five seconds in and five seconds out for one minute. ECG was recorded throughout the period of deep breathing. The results of this test were expressed as the mean of the difference between maximum and minimum heart rates for the six measured cycles in beats per minute. Value of less than or equal to 10 beats per minute is considered as abnormal.

## RESULTS

Table no. 1 depicts the comparison of age between the two groups. It shows that the average age in group-I (COPD patients) is  $54.31 \pm 2.11$  and in group-II (healthy controls) is  $53.21 \pm 1.11$  years. The two groups were age matched, so difference of age statistically non-significant ( $p > 0.05$ ) in the two groups.

Groups	Mean	± SD	p-Value
COPD Patients (Group-I)	54.31	2.11	0.083
Controls (Group-II)	53.21	1.11	

**Table 1. Comparison of Age (Mean±SD) Between COPD Patients and Normal Subjects**

Table no. 2 shows the comparative values of parameters of parasympathetic nervous system activity in COPD patients and healthy controls. The mean values of 30:15 ratio during evaluation of Parasympathetic functions, in group-I (COPD) was  $1.03 \pm 0.05$  as compared to mean

value of  $1.05 \pm 0.04$  in group-II (Normal subjects). The variation was significant at 5% significance level ( $p < 0.05$ ).

Parameters	Group-I (COPD)		Group-II (Normal)		p-Value
	Mean	±SD	Mean	±SD	
30:15 Ratio	1.03	0.05	1.05	0.04	<0.05
Valsalva Ratio	1.12	0.06	1.26	0.02	<0.001
DBT	8.66	2.56	17.79	1.82	<0.001

**Table 2. A Comparative Data of Parasympathetic Nervous System Activity in COPD Patients (Group-I) & Normal Healthy Subjects (Group-II)**

$P < 0.05$  Significant at 5% significance level.

$P < 0.001$  Highly Significant.

The mean values of Valsalva ratio in group-I (COPD) & in group-II (Normal subjects) were  $1.12 \pm 0.06$  and  $1.26 \pm 0.02$ , respectively, showing again statistically highly significant ( $p < 0.001$ ) variation.

The mean value of heart rate variation during Deep Breathing Test (DBT) in group-I (COPD) was  $8.66 \pm 2.56$  whereas it was  $17.79 \pm 1.82$  in group-II (Normal subjects). The variation was again statistically highly significant ( $p < 0.001$ ).

From the results shown above it is observed that there is significant reduction in parasympathetic activity in patients of COPD (group-I) as compared to that in normal healthy subjects (group-II).

## DISCUSSION

COPD is one of the leading diseases causing morbidity and mortality worldwide. Chronic bronchitis and emphysema which most of the times occur in association are grouped under the umbrella term COPD.<sup>8</sup> The pathogenesis and clinical manifestations of COPD are not restricted to pulmonary inflammation and structural remodelling. Rather this disorder is also associated with clinically significant systemic alterations in the biochemical and organ function. Persistent hypoxia may be associated with autonomic dysfunction in COPD patients.<sup>9</sup> This study was done on males because smoking is more prevalent in males and thus causing higher incidence of COPD in males.<sup>10</sup> The 30: 15 ratio findings of our study are consistent with another study done on hypoxic COPD patients. It was observed that patients with autonomic neuropathy had a heart rate which continued to rise throughout the observed time and thus had a ratio of  $\leq 1$ .<sup>11</sup> Valsalva ratio another tool to assess parasympathetic activity, showed highly significant variation between two study groups. Our results are in accordance with another study done on 35 patients with hypoxaemic COPD and seven age matched normal subjects.<sup>12</sup> Another study showed depressed heart rate variation in the heart rate response to different stimuli, such as the Valsalva manoeuvre in COPD patients.<sup>13</sup>

Heart rate variation with deep breathing showed a highly significant variation, supported by another study by Stewart AG et al., who observed that patients with an

autonomic neuropathy lose this heart rate variability.<sup>12</sup> These findings were consistent with some other studies as well.<sup>14,15</sup>

## CONCLUSION

There is significant decrease of parasympathetic activity in patients of chronic obstructive pulmonary disease as compared to normal subjects. Further research work to probe the autonomic nervous system dysfunction in COPD patients in relation to the duration of the disease and the variation in incidence of COPD among males and females is recommended, which is the limitation of our study.

## REFERENCES

- [1] Anto JM, Vermeire P, Vestbo J, et al. Epidemiology of chronic obstructive pulmonary disease. *Eur Respir J* 2001;17(5):982-994.
- [2] Pretto JJ, McMahon MA, Rochford PD, et al. A pilot study of inspiratory capacity and resting dyspnoea correlations in exacerbations of COPD and asthma. *Int J Chron Obstruct Pulmon Dis* 2007;2(4):651-656.
- [3] Viegi G, Pistelli F, Sherrill DL, et al. Definition, epidemiology and natural history of COPD. *Eur Respir J* 2007;30(5):993-1013.
- [4] Wouters EF, Creutzberg EC, Schols AM. Systemic effects in COPD. *Chest* 2002;121(5 Suppl):127S-130S.
- [5] Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. *CHEST* 2005;128(4):2640-2646.
- [6] Andreas S, Imminhausen L, Strasse RK. Slow breathing reduces sympathoexcitation in patients of COPD. *ERJ* 2008;32:387-392.
- [7] Bir LS, Ozkurt S, Daloglu G, et al. Impaired sympathetic skin response in chronic obstructive pulmonary disease. *Tohoku J Exp Med* 2005;207(4):243-248.
- [8] Siafakas NM, Vermeire P, Pride NB. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. *Eur Respir J* 1995;8(8):1398-1420.
- [9] Watson JP, Nolan J, Elliot MW. Autonomic dysfunction in patients with nocturnal hypoventilation in extrapulmonary restrictive diseases. *Eur Respir J* 1999;13(5):1097-1102.
- [10] Jindal SK, Aggarwal AN, Gupta D. A review of population studies from India to estimate national burden of chronic obstructive pulmonary disease and its association with smoking. *Indian J Chest Dis Allied Sci* 2001;43(3):139-147.
- [11] Hjalmarson A, Aasebo U, Aleksandersen G et al. Cardiovascular responses to tests for autonomic dysfunction in patients with chronic obstructive pulmonary disease with and without continuous long term oxygen therapy. *J Auton Nerv Syst* 1996;60(3):169-174.
- [12] Stewart AG, Marsh F, Waterhouse JC, et al. Autonomic nerve dysfunction in COPD as assessed by the acetylcholine sweat-spot test. *Eur Respir J* 1994;7(6):1090-1095.
- [13] Andreas S, Anker SD, Scanlon PD, et al. Neurohumoral activation as link to systemic manifestations of chronic lung disease. *Chest* 2005;128(5):3618-3624.
- [14] Volterrani M, Scalvini S, Mazzuero G, et al. Decreased heart rate variability in patients with chronic obstructive pulmonary disease. *Chest* 1994;106(5):1432-1437.
- [15] Shin KC, Lee KH, Park HJ, et al. Dysfunction of autonomic nervous system in patients with chronic obstructive pulmonary disease. *Tuberc Respir Dis* 1999;46(3):317-326.